Showing results (211-220 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|October 8, 2005
Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeksPeter Johnson, Thomas Geldart, Pierre Fumoleau, et al.
Investigational New Drugs|September 1, 2005
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcomaJ T Hartmann, K Oechsle, J Huober, et al.
Investigational New Drugs|September 1, 2005
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancerChristina H Yeon, Mark D Pegram
Investigational New Drugs|September 1, 2005
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancerRanjana Advani, Bert L Lum, George A Fisher, et al.
Investigational New Drugs|September 1, 2005
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) studyJohn S Macdonald, Sheryl McCoy, Robert P Whitehead, et al.
Investigational New Drugs|January 1, 1990
Comparative activity of four anthracyclines against heterotransplanted germ cell tumor linesA Harstrick, J Casper, H Köhne-Wömpner, et al.
Investigational New Drugs|May 1, 1991
Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancerJ R Rigas, M G Kris, R J Gralla, et al.
Investigational New Drugs|July 13, 2006
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group studyJames H Doroshow, Sheryl McCoy, John S Macdonald, et al.
Investigational New Drugs|May 4, 2005
Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanomaMichael J Millward, Anthony Joshua, Rick Kefford, et al.
Investigational New Drugs|June 22, 2006
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignanciesJill Gilbert, Michael A Carducci, Sharyn D Baker, et al.
Pageof 372